T-Free CBD Distillate REQUEST COA Vantage Hemp’s T-Free CBD Distillate is Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S) certified, meeting the rigorous requirements of Therapeutic Goods Order No. 93 under Australia’s Therapeutic Goods Administration (TGA).

T-free CBD Distillate

 

T-free CBD Distillate broad-spectrum API is ideal for formulations requiring multiple cannabinoids while maintaining regulatory compliance in THC-restricted markets. Its approval under TGO 93 facilitates market access in Australia’s prescription cannabis program, making it a strategic choice for global pharmaceutical manufacturers supplying cannabinoid-based formulations through Australia’s Special Access Scheme (SAS B) and Authorised Prescriber channels.

Drug developers targeting global markets will benefit from the PIC/S certification, ensuring that the API meets the highest international GMP standards for regulatory approval and commercialization.  For pharmaceutical procurement teams, this API offers broad market applicability, enhanced patient accessibility, and reduced regulatory barriers in jurisdictions that enforce strict THC limitations on cannabinoid-based therapies.

Read About Our  CBD Distillate Drug Master File

Key Characteristics of T-Free CBD Distillate

 

    • High CBD content
    • THC compliant with TGO 93 requirements in Australia
    • Total cannabinoid profile includes CBDV and CBG, offering a broader spectrum
    • Certified under Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S) for global pharmaceutical exports

Regulatory and R&D Relevance

 

    • Australia (TGA): The TGO 93 certification ensures compliance for prescription cannabis medicines, allowing export under Australia’s Special Access Scheme (SAS B) and Authorised Prescriber pathways.